BEAM
Price
$33.59
Change
-$1.82 (-5.14%)
Updated
Jan 15, 11:13 AM (EDT)
Capitalization
3.59B
47 days until earnings call
Intraday BUY SELL Signals
CAPR
Price
$23.70
Change
-$1.09 (-4.40%)
Updated
Jan 15, 11:16 AM (EDT)
Capitalization
1.35B
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs CAPR

Header iconBEAM vs CAPR Comparison
Open Charts BEAM vs CAPRBanner chart's image
Beam Therapeutics
Price$33.59
Change-$1.82 (-5.14%)
Volume$626
Capitalization3.59B
Capricor Therapeutics
Price$23.70
Change-$1.09 (-4.40%)
Volume$853
Capitalization1.35B
BEAM vs CAPR Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. CAPR commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and CAPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (BEAM: $35.41 vs. CAPR: $24.79)
Brand notoriety: BEAM and CAPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 122% vs. CAPR: 31%
Market capitalization -- BEAM: $3.59B vs. CAPR: $1.35B
BEAM [@Biotechnology] is valued at $3.59B. CAPR’s [@Biotechnology] market capitalization is $1.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileCAPR’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • CAPR’s FA Score: 0 green, 5 red.
According to our system of comparison, both BEAM and CAPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while CAPR’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 4 bearish.
  • CAPR’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than CAPR.

Price Growth

BEAM (@Biotechnology) experienced а +22.40% price change this week, while CAPR (@Biotechnology) price change was -5.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

CAPR is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.59B) has a higher market cap than CAPR($1.35B). BEAM YTD gains are higher at: 27.742 vs. CAPR (-14.103). CAPR has higher annual earnings (EBITDA): -84.92M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. CAPR (98.6M). CAPR has less debt than BEAM: CAPR (14.5M) vs BEAM (151M). BEAM has higher revenues than CAPR: BEAM (55.7M) vs CAPR (11.1M).
BEAMCAPRBEAM / CAPR
Capitalization3.59B1.35B266%
EBITDA-434.55M-84.92M512%
Gain YTD27.742-14.103-197%
P/E RatioN/AN/A-
Revenue55.7M11.1M502%
Total Cash1.08B98.6M1,090%
Total Debt151M14.5M1,041%
FUNDAMENTALS RATINGS
BEAM vs CAPR: Fundamental Ratings
BEAM
CAPR
OUTLOOK RATING
1..100
793
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3834
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (37) in the null industry is somewhat better than the same rating for CAPR (76) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than CAPR’s over the last 12 months.

CAPR's Profit vs Risk Rating (41) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that CAPR’s stock grew somewhat faster than BEAM’s over the last 12 months.

BEAM's SMR Rating (97) in the null industry is in the same range as CAPR (99) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CAPR’s over the last 12 months.

CAPR's Price Growth Rating (34) in the Biotechnology industry is in the same range as BEAM (38) in the null industry. This means that CAPR’s stock grew similarly to BEAM’s over the last 12 months.

CAPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that CAPR’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMCAPR
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
CAPR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TORCX18.610.16
+0.87%
Tortoise Energy Infrastructure TR C
EICIX18.490.15
+0.82%
EIC Value Institutional
WBEIX16.900.06
+0.36%
William Blair Emerging Mkts Growth I
FFBGX40.960.05
+0.12%
American Funds Global Balanced 529-F-3
FCMVX13.60N/A
N/A
Fidelity Mid Cap Value K6

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+2.49%
CRSP - BEAM
71%
Closely correlated
+1.26%
RXRX - BEAM
62%
Loosely correlated
+3.41%
NTLA - BEAM
61%
Loosely correlated
+2.39%
PRME - BEAM
59%
Loosely correlated
+3.61%
VIR - BEAM
57%
Loosely correlated
+8.08%
More

CAPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with VRAX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then VRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
N/A
VRAX - CAPR
48%
Loosely correlated
+7.48%
KRRO - CAPR
33%
Loosely correlated
+0.11%
BEAM - CAPR
33%
Poorly correlated
+2.49%
ACLX - CAPR
32%
Poorly correlated
+4.66%
LXEO - CAPR
32%
Poorly correlated
+3.90%
More